Penn. Medicaid savings from Pfizer Procardia XL to Bayer Adalat CC switch found in retrospective study.
Executive Summary
BAYER ADALAT CC/PFIZER PROCARDIA XL PENNSYLVANIA MEDICAID SWITCH STUDY found that the state's Medicaid program could save "more than $2.5 mil. per year" by switching hypertensive patients without angina from Procardia XL to Adalat CC, according to a study published in a recent issue of Clinical Therapeutics. The two once-a-day nifedipine calcium channel blockers were examined through a retrospective analysis of Medicaid claims data from 1993. Miles (now Bayer) Pharmaceutical Division of Health and Economics Outcomes Research staffer Robert Simons was the principal investigator.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth